SUBSCRIBE
SUBSCRIBE

Arrivo BioVentures

NEWS
Pictured: A vibrant collage with layered mind and keyhole
Drug Development
Precision Medicine and Novel Approaches on Cusp of Breaking Through in Psychiatry
Approaches and targets for depression and other mental health illnesses have remained stagnant for decades. With several readouts for novel therapies on the horizon, that could be changing.
May 21, 2024
 · 
5 min read
 · 
Kate Goodwin
Business
The Next Generation: Top 20 Life Science Startups to Watch in 2017
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
January 3, 2017
 · 
11 min read
 · 
Mark Terry
What You Need to Know About Arrivo BioVentures
Business
What You Need to Know About Arrivo BioVentures
January 3, 2017
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Serial BioPharma Entrepreneurial Team Launches Arrivo BioVentures with $49 Million
May 25, 2016
 · 
3 min read
AWARDS
  • NextGen Class of 2017
JOBS
IN THE PRESS
Press Releases
Arrivo BioVentures Begins Phase 1 Study of SP-624, the First Potential Treatment Specifically for Women with Major Depressive Disorder
October 10, 2024
 · 
3 min read
Drug Development
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator
April 16, 2024
 · 
2 min read
Business
Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor
January 3, 2024
 · 
3 min read
Bio NC
ArrivoBio Raises $45M in Series B Financing to Advance Pipeline
November 29, 2023
 · 
3 min read
Drug Development
Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder
May 26, 2022
 · 
2 min read